yahoo_financeOriginal article
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
ConferenceBHV-1530Neutral
AI Analysis
Summary
Biohaven will present new clinical data on BHV-1530, a novel FGFR3-directed antibody-drug conjugate with a proprietary topoisomerase I payload, at the ESMO Congress.
Importance:5/10
Sentiment:
0.00
ADCFGFR3Topoisomerase IESMO Congressclinical data
Related Companies
Read the original article
Published by yahoo_finance on July 20, 2026 11:30 AM